Introduction {#s1}
============

The etiology and development of cancer are a result of complex interactions between genetic and environmental factors. Physical and chemical agents originated from either endogenous processes, such as cellular metabolism, or exogenous exposure, including ionizing radiation, tobacco smoke, and genotoxic chemicals, are responsible for oxidative cell DNA damage; when left unrepaired or incorrectly repaired, cell DNA damage may lead to mutations and genomic instability [@pone.0098022-Jackson1]. Base excision repair (BER) system repairs base damage and single-strand breaks caused by X-rays, oxygen radicals, and alkylating reagents. However, inherited defects in DNA repair pathways result in the accumulation of DNA damage, cell apoptosis, or unregulated cell growth and development of malignancy [@pone.0098022-Goode1]--[@pone.0098022-Hoeijmakers1].

Poly(ADP-ribose) polymerase-1 (PARP-1), also called adenosine diphosphate ribosyl transferase, is one of the most important components of the BER system. PARP1 is a nuclear nick sensor enzyme that becomes activated in response to DNA breakage [@pone.0098022-Lockett1]. In general, PARP1 binds to the sites of DNA damage via the N-terminal DNA-binding domain and catalyzes the addition of poly(ADP-ribose) polymers from NAD+ to nuclear acceptor proteins, including histones, P53, and PARP-1 itself, thereby causing chrome relaxation and recruitment of other repair proteins (e.g., XRCC1, DNA-PK) into the damaged site [@pone.0098022-Caldecott1], [@pone.0098022-ElKhamisy1]. Therefore, PARP-1 is essential for the surveillance and maintenance of genome integrity and interaction with various proteins involved in multiple DNA repair pathways, including BER, SSBR (Single-strand break repair), and DSBR (DNA double-strand break repair). Moreover, PARP-1 is implicated in other molecular and cellular processes, such as gene transcription modulation, apoptosis decision, telomere maintenance, and chromatin remodeling [@pone.0098022-Kim1], [@pone.0098022-Yu1]. Evidence has suggested that the deficiency of PARP-1 results in DNA repair defects, genomic instability, failure of induction of cell death, and modulation of gene transcription, thereby contributing to carcinogenesis [@pone.0098022-Masutani1]--[@pone.0098022-Bieche1].

The human *PARP1* gene, located on chromosome 1q41--42, is approximately 47.3 kb in length and consists of 23 exons. Numerous single nucleotide polymorphisms (SNPs), including 17 non-synonymous SNPs, have been identified in *PARP-1*; among these SNPs, rs1136410 at codon 762 in exon 17, a non-synonymous T→C polymorphism changing valine to alanine, is the most extensively investigated. This polymorphism is located in the sixth helix of the COOH-terminal NAD-binding region with all of the catalytic activities of the full-length enzyme. This amino acid change contributes to low poly(ADP-ribosyl)ation activities in a dosage-dependent manner, thereby impairing DNA repair and enhancing the susceptibility of variant allele carriers to damage caused by environmental carcinogens and cancer risk [@pone.0098022-Lockett1], [@pone.0098022-Zaremba1]. Thus far, molecular epidemiological studies have indicated the genetic association of Val762Ala with the risk of many cancer types, including cancers of the breast, stomach, lung, cervix, brain, and colorectum, as well as other types of malignancies [@pone.0098022-Smith1]--[@pone.0098022-Santonocito1]. However, these studies have not yet produced consistent results. The discrepancies of the findings are partially attributed to the limited power of individual studies with small sample sizes and differences in the baseline characteristics of included patients. Although the *PARP-1 Val762Ala* polymorphism and susceptibility to cancers have been discussed [@pone.0098022-Pabalan1], [@pone.0098022-Yu2], all of the eligible studies have not been included, particularly case-control studies published in the past two years. Therefore, these meta-studies are disputed because of the limited number of included studies and relatively small sample size. The present meta-analysis aimed to update previous meta-analyses and derive a reliable conclusion regarding the effect of the V762A polymorphism on the function of *PARP-1* in cancer. This meta-analysis also aimed to quantify the potential of heterogeneity between studies.

Materials and Methods {#s2}
=====================

Literature search {#s2a}
-----------------

Relevant publications were identified by conducting a literature search in PubMed and EMBASE databases using the following search terms: PARP-1 or ADPR, variant or polymorphism or SNP, and cancer or carcinoma or tumor. The last search was updated on December 9, 2013. The references of the identified studies and reviews were also screened to find additional eligible studies. If studies with overlapped subjects were reported, only the one with the most complete data was included in the meta-analysis. Search results were limited to studies published in English.

Inclusion and exclusion criteria {#s2b}
--------------------------------

Studies were included in our meta-analysis if the following criteria were satisfied: (1) studies were designed as cohort or case-control; (2) studies investigated the association between *PARP-1* Val762Ala polymorphism and cancer susceptibility; and (3) sufficient genotype data were provided to estimate the odds ratio (OR) and a corresponding 95% confidence interval (CI). Studies were excluded if the following criteria were satisfied: (1) case-only, case reports, or reviews; (2) duplicate of previous publications; (3) family-based studies; and (4) based on insufficient data for calculation.

Data extraction {#s2c}
---------------

Two investigators dependently reviewed the publications and obtained information according to a standard data form. The following data were extracted from each study: name of first author; year of publication; country or region of origin; ethnicity of the study population; cancer type; number of cases and controls; allele and genotype frequency; evidence of Hardy-Weinberg equilibrium (HWE) in controls; source of controls; and genotyping method. Disagreements between the two investigators were resolved by discussing the results with a third investigator.

Statistical analysis {#s2d}
--------------------

The strength of the association between the *PARP-1* Val762Ala polymorphism and the risk of cancer was measured by OR with 95% CI in five genetic models, including dominant model (VA + AA vs. VV), recessive model (AA vs. VA + VV), homozygous model (AA vs. VV), heterozygous model (VA vs. VV), and allele model (A vs. V). The significance of the pooled OR was determined by a *Z*-test, and *P*\<0.05 was considered statistically significant. A statistical test to determine heterogeneity between studies was performed using *Q*-test and *I^2^* test. In the *Q*-test, *P*\>0.10 indicates the absence of heterogeneity. The pooled OR estimates of each study were calculated using the fixed-effect model, the Mantel-Haenszel method. Otherwise, a random-effect model, the Dersimonain and Laird method, was applied. The *I^2^* test was used to quantify the effect of heterogeneity (ranges from 0% to 100%); The test represents the proportion of inter-study variability that can be attributed to heterogeneity rather than by chance. Subgroup analyses were also performed to evaluate the potential effects of ethnicity, cancer types, source of controls, and genotyping method. Sensitivity analysis was conducted by omitting each study to identify the effect of an individual study on the pooled OR. Publication bias was qualitatively detected using Begger\'s funnel plots, and Egger\'s linear regression test was performed to determine funnel plot asymmetry (*P*\<0.05 was considered as statistically significant publication bias). All of the *P* values were two-tailed. Statistical analyses were performed using STATA version 11.0 (Stata Corporation, College Station, TX, USA).

Results {#s3}
=======

Characteristics of eligible studies {#s3a}
-----------------------------------

A total of 84 articles relevant to search keywords were identified after our literature search from PubMed and EMBASE was completed. According to the inclusion criteria, 45 studies were excluded. Among these studies, two were excluded because of a lack of genotyping data [@pone.0098022-Choi1], [@pone.0098022-Haiman1]. The flow chart of the detailed steps of study selection is shown in [Figure 1](#pone-0098022-g001){ref-type="fig"}. A total of 39 case-control studies with 16,783 cancer cases and 23,063 control subjects were included in our meta-analysis. The main characteristics of the eligible studies are listed in [Table 1](#pone-0098022-t001){ref-type="table"}. A total of 21 studies involved Caucasian populations and 18 focused on Asian populations. Among these studies, three focused on colorectal, lung, cervical, and bladder cancer, individually; and four described gastric, glioma, and breast cancer, individually. The distribution of the genotypes in the control subjects was in agreement with HWE except three studies [@pone.0098022-Miao1], [@pone.0098022-Nakao1], [@pone.0098022-Pan1].

![Flow chart of literature search and study selection.](pone.0098022.g001){#pone-0098022-g001}

10.1371/journal.pone.0098022.t001

###### Characteristics of eligible studies included in the meta-analysis.

![](pone.0098022.t001){#pone-0098022-t001-1}

  Name                                        Year       Country        Ethnicity     Cancer type      Sample size   Source   Controls in HWE   Genotyping method  
  ------------------------------------------ ------ ------------------ ----------- ------------------ ------------- -------- ----------------- ------------------- ----------------------
  Hosono [@pone.0098022-Hosono1]              2013        Japan           Asian       Endometrial          91         261           HB                 Yes                 TaqMan
  Li [@pone.0098022-Li1]                      2013        China           Asian        Colorectal          451        626          Mixed               Yes                PCR-RFLP
  Roszak [@pone.0098022-Roszak1]              2013        Poland        Caucasian       Cervical           446        491           PB                 Yes                PCR-HRM
  Xue [@pone.0098022-Xue1]                    2013        China           Asian           Lung             410        410           HB                 Yes                PCR-RFLP
  Nakao [@pone.0098022-Nakao1]                2012        Japan           Asian         Pancreas           185        1465          HB                 No                  TaqMan
  Pan [@pone.0098022-Pan1]                    2012        China           Asian         Gastric            176        308          Mixed               No                MassARRAY
  Santonocito [@pone.0098022-Santonocito1]    2012        Italy         Caucasian       Melanoma           167         99           NM                 Yes                PCR-HRM
  Santos [@pone.0098022-Santos1]              2012       Potugal        Caucasian       Thyroid            108        216           HB                 Yes                 TaqMan
  Wen [@pone.0098022-Wen1]                    2012        China           Asian         Gastric            307        307          Mixed               Yes               MassARRAY
  Ye [@pone.0098022-Ye1]                      2012        China           Asian         Cervical           539        800           HB                 Yes                 MA-PCR
  Yuan [@pone.0098022-Yuan1]                  2012        China           Asian      Head and neck         395        883           PB                 Yes                 TaqMan
  Zhang [@pone.0098022-Zhang2]                2012        China           Asian         Cervical           80         176           HB                 Yes          SNPware 12plex assay
  Yosunkaya [@pone.0098022-Yosunkaya1]        2010        Turkey        Caucasian        Glioma            119        180           PB                 Yes                PCR-RFLP
  Gao [@pone.0098022-Gao1]                    2010          US          Caucasian       Prostate           453        119           HB                 Yes                Sequence
  Jin [@pone.0098022-Jin1]                    2010        Korea           Asian           NHL              573        721           PB                 Yes                PCR-HRM
  Rajaraman [@pone.0098022-Rajaraman1]        2010          US          Caucasian        Glioma            340        463           HB                 Yes                 TaqMan
  Rajaraman                                   2010          US          Caucasian      Meningioma          121        463           HB                 Yes                 TaqMan
  Rajaraman                                   2010          US          Caucasian   Acoustic neuroma       65         463           HB                 Yes                 TaqMan
  Wang [@pone.0098022-Wang3]                  2010        China           Asian         Bladder            234        253           HB                 Yes                PCR-RFLP
  Liu [@pone.0098022-Liu1]                    2009          US          Caucasian        Glioma            372        365           PB                 Yes               MassARRAY
  McKean [@pone.0098022-McKeanCowdin1]        2009          US          Caucasian     Glioblastoma         987        1935         Mixed               Yes               MassARRAY
  Zhang [@pone.0098022-Zhang3]                2009        China           Asian         Gastric            236        320           HB                 Yes                PCR-RFLP
  Chiang[@pone.0098022-Chiang1]               2008        China           Asian         Thyroid            283        469           HB                 Yes                 TaqMan
  Smith[@pone.0098022-Smith1]                 2008          US          Caucasian        Breast            314        397           HB                 Yes               MassARRAY
  Berndt[@pone.0098022-Berndt1]               2007          US          Caucasian      Colorectal          649        659           NM                 Yes                 TaqMan
  Cao[@pone.0098022-Cao1]                     2007        France        Caucasian        Breast            83         100           HB                 Yes                Sequence
  Figueroa[@pone.0098022-Figueroa1]           2007        Spain         Caucasian       Bladder           1138        1131          HB                 Yes                 TaqMan
  Li[@pone.0098022-Li2]                       2007          US          Caucasian    Head and neck         830        854           HB                 Yes                PCR-RFLP
  Stern[@pone.0098022-Stern1]                 2007      Singapore         Asian        Colorectal          307        1173          PB                 Yes                 TaqMan
  Landi[@pone.0098022-Landi1]                 2006   Multiple regions   Caucasian         Lung             292        307           HB                 Yes                  APEX
  Li[@pone.0098022-Li3]                       2006          US          Caucasian       Melanoma           602        603           HB                 Yes                PCR-RFLP
  Miao[@pone.0098022-Miao1]                   2006        China           Asian         Gastric            500        1000          PB                 No                 PCR-RFLP
  Shen[@pone.0098022-Shen1]                   2006          US          Caucasian         NHL              455        535           PB                 Yes                 TaqMan
  Wu[@pone.0098022-Wu1]                       2006          US          Caucasian       Bladder            606        595           HB                 Yes                 TaqMan
  Zhai[@pone.0098022-Zhai1]                   2006        China           Asian          Breast            302        639           HB                 Yes                PCR-RFLP
  Zhang[@pone.0098022-Zhang4]                 2006          US          Caucasian        Breast           1715        1371          PB                 Yes                 TaqMan
  Zhang[@pone.0098022-Zhang1]                 2005        China           Asian           Lung            1000        1000          HB                 Yes                PCR-RFLP
  Hao[@pone.0098022-Hao1]                     2004        China           Asian        Esophageal          414        479           HB                 Yes                PCR-RFLP
  Lockett[@pone.0098022-Lockett1]             2004          US          Caucasian       Prostate           438        427           HB                 Yes               MassARRAY

PB: population-based; HB: hospital-based; HWE: Hardy-Winberg equilibrium. Genotyping method: PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; MassARRAY: genotyping was performed using the Sequenom MassARRAY iPLEXTM platform2. MassARRAY Workstation version 3.3 software was used to process and analyze iPLEX SpectroCHIP bioarrays; PCR-HRM, PCR cycling and high resolution melting analysis was performed on the Rotor-Gene 6000TM. APEX: polymorphism was analyzed together for a given sample by a microarray technique based on the arrayed primer extension principle.

Quantitative synthesis {#s3b}
----------------------

The meta-analysis findings of the correlation between *PARP-1* V762A and cancer risk are summarized in [Table 2](#pone-0098022-t002){ref-type="table"}. After the 39 studies were pooled into meta-analysis, no evidence of a significant association between V762A polymorphism and cancer risk was observed (dominant model: OR = 1.03, 95% CI = 0.95--1.11; recessive model: OR = 1.10, 95% CI = 0.97--1.26; homozygous model: OR = 1.13, 95% CI = 0.98--1.31; heterozygous model: OR = 1.02, 95% CI = 0.95--1.10; allele model: OR = 1.04, 95% CI = 0.97--1.11; [Table 2](#pone-0098022-t002){ref-type="table"}; [Figure 2](#pone-0098022-g002){ref-type="fig"}). We excluded three studies with genotypic distribution in control subjects that deviated from HWE and found that the results did not significantly alter from the corresponding pooled OR ([Table 2](#pone-0098022-t002){ref-type="table"}).

![Forest plot for pooled OR of association between the *PARP-1 Val762Ala* polymorphism and overall cancer risk under dominant model (VA+AA vs. VV).](pone.0098022.g002){#pone-0098022-g002}
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###### Meta-analysis of the association between PARP-1 Val762Ala polymorphism and cancer risk.

![](pone.0098022.t002){#pone-0098022-t002-2}

                            No. of subjects cases/controls   n                       VA+AA vs. VV                      AA vs. VA+VV                       AA vs. VV                        VA vs. VV                        A vs. V                                                                                                                                                  
  ------------------------ -------------------------------- ---- ---------------------------------------------------- -------------- ---------------------------------------------------- ----------- ---------------------------------------------------- ------- ---------------------------------------------------- ------- ---------------------------------------------------- -------
  **Total**                          16783/23063             39                   1.03 (0.95--1.11)                       0.000                       1.10 (0.97--1.26)                      0.000                     1.13 (0.98--1.31)                    0.000                   1.02 (0.95--1.10)                    0.001                   1.04 (0.97--1.11)                    0.000
  **Controls in HWE**                15922/20290             36                   1.01 (0.94--1.09)                       0.000                       1.09 (0.95--1.29)                      0.000                     1.11 (0.96--1.28)                    0.000                   1.00 (0.94--1.08)                    0.001                   1.03 (0.96--1.10)                    0.000
  **Ethnicities**                                                                                                                                                                                                                                                                                                                                                                    
  Caucasian                          10300/11773             21                   0.93 (0.83--1.03)                       0.000                       0.95 (0.76--1.18)                      0.079                     0.92 (0.78--1.08)                    0.111                   0.94 (0.84--1.04)                    0.000                   0.96 (0.87--1.05)                    0.000
  Asian                               6483/11290             18   1.17 (1.09--1.25)[\*](#nt103){ref-type="table-fn"}      0.249       1.09 (1.03--1.39)[\*](#nt103){ref-type="table-fn"}     0.000     1.28 (1.08--1.51)[\*](#nt103){ref-type="table-fn"}   0.000   1.12 (1.04--1.20)[\*](#nt103){ref-type="table-fn"}   0.805   1.12 (1.05--1.21)[\*](#nt103){ref-type="table-fn"}   0.001
  **Cancer type**                                                                                                                                                                                                                                                                                                                                                                    
  Colorectal                          1407/2458              3                    1.08 (0.93--1.25)                       0.122                       1.14 (0.79--1.67)                      0.064                     1.18 (0.76--1.85)                    0.039                   1.05 (0.90--1.23)                    0.419                   1.08 (0.88--1.31)                    0.032
  Cervical                            1065/1467              3    1.26 (1.06--1.50)[\*](#nt103){ref-type="table-fn"}      0.444                       1.59 (0.82--3.07)                      0.011                     1.68 (0.91--3.10)                    0.036                   1.14 (0.95--1.36)                    0.252   1.31 (1.16--1.48)[\*](#nt103){ref-type="table-fn"}   0.201
  Lung                                1702/1717              3    1.16 (1.00--1.33)[\*](#nt103){ref-type="table-fn"}      0.234       1.32 (1.09--1.61)[\*](#nt103){ref-type="table-fn"}     0.487     1.42 (1.14--1.76)[\*](#nt103){ref-type="table-fn"}   0.326                   1.10 (0.95--1.28)                    0.447   1.16 (1.05--1.28)[\*](#nt103){ref-type="table-fn"}   0.182
  Gastric                             1219/1935              4    1.33 (1.14--1.55)[\*](#nt103){ref-type="table-fn"}      0.222                       1.22 (0.77--1.94)                      0.001                     1.38 (0.84--2.26)                    0.002   1.28 (1.09--1.51)[\*](#nt103){ref-type="table-fn"}   0.742                   1.19 (0.95--1.48)                    0.006
  Glioma                              1818/2943              4    0.78 (0.69--0.89)[\*](#nt103){ref-type="table-fn"}      0.907                       1.06 (0.46--2.42)                      0.013                     0.92 (0.48--1.78)                    0.071   0.79 (0.68--0.91)[\*](#nt103){ref-type="table-fn"}   0.302   0.84 (0.75--0.95)[\*](#nt103){ref-type="table-fn"}   0.414
  Bladder                             1978/1979              3                    1.09 (0.86--1.39)                       0.083                       0.96 (0.69--1.33)                      0.818                     0.99 (0.70--1.40)                    0.850                   1.10 (0.84--1.44)                    0.057                   1.08 (0.96--1.22)                    0.159
  Breast                              2414/2507              4                    0.94 (0.83--1.07)                       0.203                       0.92 (0.71--1.19)                      0.852                     0.89 (0.68--1.17)                    0.838                   0.95 (0.84--1.08)                    0.176                   0.95 (0.86--1.05)                    0.317
  Other                               4489/6391              11                   1.02 (0.88--1.19)                       0.005                       0.98 (0.78--1.22)                      0.075                     0.99 (0.76--1.30)                    0.024                   1.01 (0.89--1.15)                    0.048                   1.02 (0.90--1.16)                    0.001
  **Source of controls**                                                                                                                                                                                                                                                                                                                                                             
  PB                                  4882/6719              9                    1.02 (0.87--1.19)                       0.001                       1.17 (0.90--1.51)                      0.003                     1.18 (0.88--1.59)                    0.001                   1.03 (0.89--1.20)                    0.013                   1.07 (0.94--1.22)                    0.000
  HB                                  9164/12410             24                   1.03 (0.93--1.13)                       0.002                       1.12 (0.94--1.33)                      0.001                     1.15 (0.95--1.39)                    0.001                   1.01 (0.93--1.10)                    0.04                    1.03 (0.95--1.12)                    0.000
  Mixed                               1921/3176              4                    1.03 (0.79--1.34)                        0.01                       0.98 (0.67--1.42)                      0.019                     1.03 (0.69--1.55)                    0.02                    1.03 (0.80--1.33)                    0.028                   0.99 (0.80--1.23)                    0.002
  **Genotyping method**                                                                                                                                                                                                                                                                                                                                                              
  PCR-RFLP                            5098/6364              11                   1.09 (0.93--1.27)                       0.000       1.29 (1.07--1.55)[\*](#nt103){ref-type="table-fn"}     0.008     1.34 (1.07--1.67)[\*](#nt103){ref-type="table-fn"}   0.002                   1.03 (0.90--1.19)                    0.004                   1.10 (0.98--1.24)                    0.000
  TaqMan                              6458/10147             14                   1.02 (0.92--1.12)                       0.055                       0.97 (0.85--1.12)                      0.866                      1.0 (0.86--1.16)                    0.628                   1.04 (0.96--1.12)                    0.118                   1.00 (0.93--1.09)                    0.061
  MassARRAY                           2594/3739              6                    0.89 (0.75--1.07)                       0.051                       0.90 (0.71--1.13)                      0.134                     0.93 (0.73--1.20)                    0.133                   0.94 (0.76--1.15)                    0.063                   0.93 (0.79--1.10)                    0.039
  Other                               2261/2330              6                    1.16 (0.89--1.50)                       0.005                       1.42 (0.73--2.74)                      0.000                     1.44 (0.73--2.85)                    0.000                   1.10 (0.87--1.40)                    0.031                   1.18 (0.92--1.52)                    0.000

*Phet*: *P*-value of Q-test for heterogeneity test. The fixed-effects model was used when *P*-value for heterogeneity test \>0.10; otherwise, the random-effects model was used.

**\***indicate significant difference.

Significant heterogeneity was observed among the overall 39 studies of the *PARP-1* V762A polymorphism (e.g., dominant model: Q = 98.58 on 38 d.f., *P* = 0.000, *I^2^* = 61.5%). To explore the source of heterogeneity, we performed stratified analyses on ethnicity, cancer type, source of controls, and genotyping method. In the subgroup analysis of ethnicity, *PARP-1* V762A was significantly associated with an increased risk of cancer in Asian populations in all of the genetic models (e.g., dominant model: OR = 1.17, 95% CI = 1.09--1.25; [Table 2](#pone-0098022-t002){ref-type="table"}; [Figure 3](#pone-0098022-g003){ref-type="fig"}). However, no significant association was found in Caucasian populations in any models (e.g., dominant model: OR = 0.93, 95% CI = 0.83--1.03; [Table 2](#pone-0098022-t002){ref-type="table"}; [Figure 3](#pone-0098022-g003){ref-type="fig"}). The studies were further stratified on the basis of cancer type and the results showed that *PARP-1* V762A polymorphism may be a risk factor of lung cancer in all of the genetic models except the heterozygous model (dominant model: OR = 1.16, 95% CI = 1.00--1.33; recessive model: OR = 1.32, 95% CI = 1.09--1.61; homozygous model  =  OR = 1.42, 95% CI: 1.14--1.76; heterozygous model  =  OR = 1.10, 95% CI = 0.95--1.28; allele model: dominant model: OR = 1.16, 95% CI = 1.05--1.28; [Table 2](#pone-0098022-t002){ref-type="table"}; [Figure 4](#pone-0098022-g004){ref-type="fig"}). We also found significant correlation between the Ala carrier of *PARP-1* V762A polymorphism and increased risk of cervical cancer (dominant model: OR = 1.26, 95% CI = 1.06--1.50; allele model: OR = 1.31, 95% CI = 1.16--1.48) and gastric cancer (dominant model: OR = 1.33, 95% CI = 1.14--1.55; heterozygous model: OR = 1.28, 95% CI = 1.09--1.51). By contrast, the *PARP-1* V762A polymorphism was significantly associated with a decreased risk of glioma in three genetic models ([Table 2](#pone-0098022-t002){ref-type="table"}; [Figure 4](#pone-0098022-g004){ref-type="fig"}). However, studies on colorectal, bladder, breast, and other cancer types have suggested null association (OR = 0.92--1.18; [Table 2](#pone-0098022-t002){ref-type="table"}; [Figure 4](#pone-0098022-g004){ref-type="fig"}). Furthermore, V762A polymorphism was significantly associated with increased cancer risk in the subgroup of PCR-RFLP genotyping method (recessive model: OR = 1.29, 95% CI = 1.07--1.55; homozygous model: OR = 1.34, 95% CI = 1.07--1.67; [Table 2](#pone-0098022-t002){ref-type="table"}). No significant associations were detected when the studies were stratified on the basis of the source of control subjects ([Table 2](#pone-0098022-t002){ref-type="table"}).

![Subgroup analysis by ethnicity of ORs for cancer risk associated with the *PARP-1 Val762Ala* polymorphism under dominant model (VA+AA vs. VV).](pone.0098022.g003){#pone-0098022-g003}

![Subgroup analysis by cancer type of ORs for cancer risk associated with the *PARP-1 Val762Ala* polymorphism under dominant model (VA+AA vs. VV).](pone.0098022.g004){#pone-0098022-g004}

Considering that PARP-1 functionally interacts with XRCC1 in BER processes, we performed a gene-gene interaction analysis of the five studies that reported joint effects between *PARP1 Val762Ala* and *XRCC1 Arg399Gln* on cancer risks. In [Table 3](#pone-0098022-t003){ref-type="table"}, a significant interaction between the pairwise-coding SNPs in *XRCC1-PARP1* was found because subjects with the *PARP1 Ala/Ala* and *XRCC1 Gln/Gln* genotypes exhibited a higher risk of cancer compared with subjects carrying the *PARP1 Val/Val* and *XRCC1 Arg/Arg* genotypes (pooled OR = 3.53, 95% CI = 1.30--9.59).

10.1371/journal.pone.0098022.t003

###### Pooled analysis of the interaction effects between *PARP1 Val76*2*Ala* and *XRCC1 Arg399Gln* on overall cancer risk.

![](pone.0098022.t003){#pone-0098022-t003-3}

  XRCC1 Arg399Gln                   PARP1 Val762Ala   No. of subjects cases/controls                      OR (95% CI)                         P     Phet
  -------------------------------- ----------------- -------------------------------- ---------------------------------------------------- ------- -------
  **Arg/Arg**                         **Val/Val**                282/536                                       1                                   
  **Either variant genotype**          1142/1668            1.32 (0.94--1.87)                                0.111                          0.016  
  **Both heterozygous genotype**       875/1097             1.62 (0.96--2.71)                                0.068                          0.000  
  **Gln/Gln**                         **Ala/Ala**                 67/52                3.53 (1.30--9.59)[\*](#nt106){ref-type="table-fn"}   0.014   0.067

Either variant genotype: an individual with any variant homozygote or heterozygote at one site and wild-type homozygote at the other site.

Both heterozygous genotype: an individual with heterozygote at both sites.

**\***indicate significant difference.

Sensitivity analysis {#s3c}
--------------------

Sensitivity analysis was conducted to verify the effect of each study on the overall OR by repeating the meta-analysis, but any single study was omitted at each time. In [Figure 5](#pone-0098022-g005){ref-type="fig"}, no individual study affected the pooled OR qualitatively, indicating that the pooled results were statistically robust.

![Sensitivity analysis of overall OR coefficients for dominant model (VA+AA vs. VV).\
The analysis was conducted by omitting each study in turn. Meta-analysis random-effects estimates were used. The two ends of the dotted lines represent the 95%CI.](pone.0098022.g005){#pone-0098022-g005}

Publication bias {#s3d}
----------------

Begger\'s funnel plot and Egger\'s test were performed to evaluate the publication bias of the studies. The shape of the funnel plots showed that the dots were nearly symmetrically distributed predominantly in pseudo 95% confidence limits (dominant model, [Figure 6](#pone-0098022-g006){ref-type="fig"}). The results of Egger\'s test statistically confirmed the absence of publication bias in the dominant model (*t* = −0.11, *P* = 0.916).

![Begger\'s funnel plot of publication bias for *PARP-1 Val762Ala* polymorphism with cancer risk under dominant model (VA+AA vs. VV).\
Each dot represents a separate study for the indicated association. Funnel plot of all 39 eligible studies *P* = 0.753, Egger\'s test *P* = 0.916.](pone.0098022.g006){#pone-0098022-g006}

Discussion {#s4}
==========

PARP-1, the first discovered member of the PARP family, is involved in various important molecular and cellular processes, including cellular stress response, cell cycle control, telomere maintenance, chromatin remodeling, and mitotic apparatus functions. This nuclear DNA binding protein also functions in DNA single-strand break repair. This protein specifically detects DNA strand breaks generated by different genotoxic agents, facilitates the formation of DNA repair complexes, such as BRCA1 or BRCA2, and activates regulatory enzymes, namely, ATM and ATR, involved in the cell cycle [@pone.0098022-Dent1]. Gene polymorphisms may also influence the rate of gene transcription, the stability of mRNA, or the quantity and activity of the resulting protein [@pone.0098022-Wang1]. Thus, variations in *PARP-1* gene may affect DNA repair in normal populations and facilitate cancer development in normal or exposed individuals.

Thus far, approximately 1,066 single-nucleotide polymorphisms in the *PARP-1* gene have been reported; among these polymorphisms, a T to C nucleotide transition results in Val762Ala substitution located in the C-terminal catalytic site and characterizes a commonly occurring *PARP-1* polymorphism; this alteration is frequently investigated because of its association with cancer risk [@pone.0098022-Cottet1]. Several in vitro experiments have characterized the functional effect of this polymorphism on PARP1. For instance, Wang et al. [@pone.0098022-Wang2] found that *PARP-Ala762* displays approximately half of the activity of *PARP-Val762* for both auto-poly(ADP-ribosyl)ation and trans-poly(ADP-ribosyl)ation of histone H1. Lockett et al. [@pone.0098022-Lockett1] also suggested that the *PARP-1 Val762Ala* polymorphism reduces the enzymatic activity of PARP1 in response to oxidative damage. Molecular epidemic studies have also been conducted to investigate the functional relevance of this variant with susceptibility to cancer. However, results remain inconsistent.

A total of 39 studies with 16,783 cancer cases and 23,063 controls were considered in the present meta-analysis. The results indicated no significant association of *PARP-1 Val762Ala* polymorphism with overall cancer risk. In the stratified analysis by ethnicity, the variant --762Ala allele was significantly associated with an increased cancer risk among Asian populations. By contrast, no significant correlation was detected among Caucasians. The discrepancy in ethnicity could be attributed to the evident difference in the minor allele frequency (MAF) of *Val762Ala* polymorphism in Asians and Caucasians in our meta-analysis (41.6% and 16.2%, respectively). This genetic polymorphism variance with ethnicity was consistent with those described in a previous study [@pone.0098022-Jiang1]. Significant risks were also found in subgroup analysis based on cancer types. Subjects with the variant Ala allele were more susceptible to cancers of the cervix, lung, and stomach, whereas the polymorphism was a potential protective factor against glioma in dominant, heterozygous, and allele models. *PARP-1* variant genotypes may possibly be tissue specific because of high or low PARP-1 expression levels in different tumor tissues [@pone.0098022-Bieche1], [@pone.0098022-Ghabreau1]. Moreover, this result could be interpreted partially on the basis of the different functions of PARP-1 in different tumor types as a result of distinct mechanisms in terms of cancer susceptibility. In addition, stratified analysis by genotyping techniques indicated that studies involving PCR-RFLP assay likely acquired significant results in the overall comparison. This trend is possible because studies involving Asians mainly utilized PCR-RFLP. In studies involving Caucasians, Taqman and MassArray were the main genotyping techniques. Considering gene-gene interaction analysis, we found a significant joint effect of *ERCC1* --*399Gln* and PARP-1--*762Ala* on increased cancer risk in a homozygous genetic model. However, this result should be carefully interpreted because of a relatively small sample size; moreover, this result should be confirmed by conducting further analysis of additional published studies.

Compared with two previous meta-analyses, our meta-analysis involved a remarkably larger number of studies (39 vs. 21 and 28) and provided a more comprehensive and reliable conclusion. Pooling the data from 39 studies, we reconfirmed the function of *PARP-1 Val762Ala* in increased cancer risk among Asian populations. Furthermore, cancer types in the study were more multifarious (seven types) and a significant association was found in cervical, lung, and gastric cancers, as well as glioma. In addition, the potential interaction effect of *XRCC1 Arg399Gln* on *PARP-1 Val762Ala* was also evaluated in the present analysis.

Some potential limitations of this study should also be considered. First, the pooled results were based on unadjusted estimates because not all of the studies provided adjusted ORs; when these studies revealed adjusted ORs, these ORs were not adjusted by the same confounders. Hence, a precise analysis should be performed if individual data, such as age, sex, BMI, and smoking and drinking status, were available. Second, several factors, such as gene-gene or gene-environment interaction, may influence gene-disease factor. The joint effect between *PARP-1 Val762Ala* and *XRCC1 Arg399Gln* genotypes on the risk of cancer was addressed in the present study. However, the lack of individual data from the included studies limited the further evaluation of other potential interactions, as in other genes and environment factors. For instance, only two studies have reported the combined effect of *XRCC1 Arg194Trp* and *PARP-1 Val762Ala* genotypes on the risk of cancer [@pone.0098022-Pan1], [@pone.0098022-Wen1]. Third, only articles written in English were included; as such, bias may be observed in our meta-analysis.

In conclusion, the present meta-analysis provided strong evidence of the association of *PARP-1 Val762Ala* with increased cancer risk among Asian populations. The same results were observed in the subgroups of gastric, cervical, and lung cancers, as well as in studies using PCR-RFLP genotyping method. Our findings suggested that the *PARP-1 Val762Ala* polymorphism may function in cancer development in an ethnicity- or cancer-specific manner. Well-designed epidemiological studies should be conducted by carefully matching cases and control subjects to verify our observations. Further studies may focus on the influence of gene-gene and gene-environment interactions on the association of cancer and *PARP-1 Val762Ala* polymorphism.

Supporting Information {#s5}
======================

###### 

**PRISMA checklist.**

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: QQ JL HCZ. Performed the experiments: QQ JL HCZ LPX LLZ XY. Analyzed the data: QQ JL HCZ XY CZ HYC XCS. Contributed reagents/materials/analysis tools: XY CZ. Wrote the paper: QQ.
